Objective  To provide pharmaceutical monitoring using the Pharmaceutical Care Network Europe (PCNE) for patients with respiratory diseases, to explore effective pharmaceutical monitoring models in the department of respiratory, and to promote clinical rational drug use.

Methods  Inpatients diagnosed with chronic obstructive pulmonary disease (COPD) and lung infections in 2022 at the First Affiliated Hospital of Anhui University of Science and Technology were selected and divided into a simple group and an intervention group. According to the PCNE classification system, the types, causes, interventions, acceptance of interventions, and resolution status of drug-related problems (DRPs) were analyzed.

Results  A total of 120 cases were included, 60 cases in the simple group and 60 cases in the intervention group. Regarding the number of DRPs, there were 15 cases in the simple group and 45 cases in the intervention group, and there was a significant difference between the two groups (P<0.05). There were a total of 82 DRPs, which were mainly related to therapeutic efficacy (51.22%) and safety (46.34%), and the reasons for this were that patients' incorrect medication usage method, inappropriate usage and dosage, and unscheduled safety monitoring, etc. The pharmacist interventions were 75 (91.46%) at the drug level, 38 (46.34%) at the physician level, and 43 (52.44%) at the patient level; after the pharmacist interventions, the acceptance rate was in the range of 97.56%, and 74.39% of the DRPs were resolved.

Conclusion  PCNE classification system helps clinical pharmacists to enhance their ability to find and deal with DRPs, reduce the risk of clinical adverse events and promote reasonable and safe drug use. Meanwhile, it is conducive to the standardization of pharmaceutical care records for patients with respiratory diseases and provides reference for pharmaceutical service models for patients in the department of respiratory.

1.肖坚, 黄娅敏, 刘可可, 等. 运用欧洲药学监护联盟分类系统处理药物相关问题促进药学监护发展[J]. 药物流行病学杂志, 2019, 28(8): 553-556. [Xiao J, Huang YM, Liu KK, et al. Pharmaceutical Care Network Europe classification system used to treat drug-related problems to promote the development of pharmaceutical care[J]. Chinese Journal of Pharmacoepidemiology, 2019, 28(8): 553-556.] DOI: 10.19960/j.cnki.issn1005-0698.2019.08.015.

2.Maes KA, Tremp RM, Hersberger KE, et al. Demonstrating the clinical pharmacist's activity: validation of an intervention-oriented classification system[J]. Int J Clin Pharm, 2015, 37(6): 1162-1171. DOI: 10.1007/s11096-015-0179-z.

3.瞿慧君, 廖赟, 李琴, 等. 欧洲医药保健网分类系统用于解决呼吸科药物相关问题的效果评价 [J]. 中国药房, 2018, 29(2): 276-279. [Qu HJ, Liao Y, Li Q, et al. Effect evaluation of Pharmaceutical Care Network Europe classification system on drug-related problems in respiration department[J]. China Pharmacy, 2018, 29(2): 276-279.] DOI: 10.6039/j.issn.1001-0408.2018.02.31.

4.瞿慧君, 廖赟, 张萍, 等. 运用PCNE分类系统对COPD和脑卒中患者进行药学监护的前瞻性队列研究[J]. 中国医院药学杂志, 2018, 38(21): 2276-2280. [Qu HJ, Liao Y, Zhang P, et al. A prospective study of pharmaceutical care in patients with COPD and stroke on the PCNE classification system[J]. Chinese Journal of Hospital Pharmacy, 2018, 38(21): 2276-2280.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.21.18.

5.李慧馨, 蔡俊, 张雨昇, 等. PCNE分类系统在老年高血压患者药物相关问题中的应用[J]. 中南药学, 2021, 19(3): 528-533. [Li HX, Cai J, Zhang YS, et al. Applicationof PCNE classification system in drug-related problems among elderly patients with hypertension[J]. Central South Pharmacy, 2021, 19(3): 528-533.] DOI: 10.7539/j.issn.1672-2981.2021.03.027.

6.谢龙, 谈震, 曲国红, 等. 欧洲药学监护网络基金会分类系统在老年2型糖尿病高血压病人药物相关问题中的应用[J]. 安徽医药, 2022, 26(5): 1052-1057. [Xie L, Tan Z, Qu GH, et al. Application of Pharmaceutical Care Network Europe classification system to drug-related problems in type 2 diabetes elderly patients with hypertension[J]. Anhui Medical and Pharmaceutical Journal, 2022, 26(5): 1052-1057.] DOI: 10.3969/j.issn.1009-6469.2022.05.048.

7.白向荣, 程红勤, 金颖, 等. 欧洲医药保健网分类系统在呼吸科老年人多重用药中的应用研究[J]. 实用药物与临床, 2020, 23(7): 669-672. [Bai XR, Cheng HQ, Jin Y, et al. Application of Pharmaceutical Care Network Europe classification system for management of polypharmacy in elderly patients in respiratory department[J]. Practical Pharmacy and Clinical Remedies, 2020, 23(7): 669-672.] DOI: 10.14053/j.cnki.ppcr.202007020.

8.孙玉鹤, 吕景娣, 王婷, 等. 欧洲医药保健网分类系统在产科药物相关问题中的应用[J]. 中南药学, 2022, 20(10): 2420-2425. [Sun YH, Lyu JD, Wang T, et al. Role of classification system in Pharmaceutical Care Network Europe in the drug related problems in the obstetrics department[J]. Central South Pharmacy, 2022, 20(10): 2420-2425.] DOI: 10.7539/j.issn.1672-2981.2022.10.036.

9.彭苗苗, 张桂凡. 引入PCNE分类系统对消化内科药物相关问题进行探索与实践[J].中南药学, 2022, 20(11): 2683-2688. [Peng MM, Zhang GF. PCNE classification system for drug-related problems in the department of gastroenterology[J]. Central South Pharmacy, 2022, 20(11): 2683-2688.] DOI: 10.7539/j.issn.1672-2981.2022.11.038.

10.Classification for drug related problems V9.0[EB/OL]. (2019-02-20) [2022-01-10]. https://www.pcne.org/upload/files/334_PCNE_ classification_V9-0.pdf.

11.Garcia-Caballos M, Ramos-Diaz F, Jimenez-Moleon JJ, et al．Drug-related problems in older people after hospital discharge and interventions to reduce them[J]. Age Ageing, 2010, 39(4): 430-438. DOI: 10.1093/ageing/afq045.

12.陈龙, 李霞, 黄玲梅, 等. 慢性阻塞性肺疾病221例的药物相关问题回顾性分析[J]. 药品评价, 2022, 19(7): 434-438. [Cheng L, Li X, Huang LM, et al. Retrospective analysis of problems related to medication of patients with chronic obstructive pulmonary disease[J]. Drug Evaluation, 2022, 19(7): 434-438.] DOI: 10.19939/j.cnki.1672-2809.2022.07.14.

13.药飞. 哮喘慢性阻塞性肺疾病患者吸入制剂操作错误情况及影响因素分析[J]. 山西医药杂志, 2021, 50(15): 2318-2320. [Yao F. Analysis of inhaled preparation operation errors and influencing factors in asthmatic patients with chronic obstructive pulmonary disease[J]. Shanxi Medical Journal, 2021, 50(15): 2318-2320.] DOI: 10.3969/j.issn.0253-9926.2021.15.019.

14.Lewis A, Torvinen S, Dekhuijzen PN, et al.The economic burden of asthma andchronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries[J]. BMC Health Serv Res, 2016, 16: 251. DOI: 10.1186/s12913-016-1482-7.

15.香雪芳. 基于DRPs的药师参与分类药学监护对慢性阻塞性肺疾病患者用药安全性和监护质量的影响 [J]. 中国现代药物应用, 2023, 17(2): 156-160. [Xiang XF. Impact of DRPs-based pharmacist's participation in classified pharmaceutical care on medication safety and monitoring quality in patients with chronic obstructive pulmonary disease[J]. Chinese Journal of Modern Drug Application, 2023, 17(2): 156-160.] DOI: 10.14164/j.cnki.cn11-5581/r.2023.02.046.

16.支气管扩张症专家共识撰写协作组, 中华医学会呼吸病学分会感染学组. 中国成人支气管扩张症诊断与治疗专家共识[J]. 中华结核和呼吸杂志, 2021, 44(4): 311-321. DOI: 10.3760/cma.j.cn112147-20200617-00717.

17.国家卫生健康委员会. 关于印发质子泵抑制剂临床应用指导原则(2020年版）的通知[EB/OL]. (2020-12-09)[2022-07-01]. 错误!超链接引用无效。.

18.Weimann A, Braga M, Carli F, et al. ESPEN practical guideline: clinical nutrition in surgery[J]. Clin Nutr, 2021, 40(7): 4745-4761. DOI: 10.1016/j.clnu.2021.03.031.

19.李文喆, 刘洋, 吴茜, 等. 基于欧洲医药保健网分类系统的某中医医院重症医学科药物相关问题的分析[J]. 中国医院用药评价与分析, 2021, 21(2): 232-236. [Li WZ, Liu Y, Wu Q, et al. Analysis on drug-related problems in department of intensive care unit in a certain hospital of traditional Chinese medicine based on the classification system of Pharmaceutical Care Network Europe[J]. Evaluation and analysis of drug-use in hospitals of China, 2021, 21(2): 232-236.] DOI: 10.14009/j.issn.1672-2124.2021.02.025.

20.Zhu Y, Liu C, Zhang Y, et al. Identification and resolution of drug-related problems in a tertiary hospital respiratory unit in china[J]. Int J Clin Pharm, 2019, 41(6): 1570-1577. DOI: 10.1007/s11096-019-00922-3.

21.曾晨欣, 王皓, 吴秋惠, 等. 药学服务中药物相关问题的研究进展[J]. 中国药房, 2018, 29(16): 2291-2295. [Zeng CX, Wang H, Wu QH, et al. Research progress of drug-related problems in pharmaceutical care[J]. China Pharmacy, 2018, 29(16): 2291-2295.] DOI: 10.6039/j.issn.1001-0408.2018.16.28.

22.王弈冬, 岳晓萌, 史宁, 等. 药物相关问题的国际监测干预与经济性分析[J]. 中国药物应用与监测, 2011, 8(3): 176-180. [Wang YD, Yue XM, Shi N, et al. International monitoring, pharmaceutical intervention and economic analysis of drug-related problems[J]. Chinese Journal of Drug Application and Monitoring, 2011, 8(3):176-180.] DOI: 10.3969/j.issn.1672-8157. 2011.03.015.